跳轉至內容
Merck
全部照片(1)

重要文件

SML0325

Sigma-Aldrich

瑞替加滨

≥98% (HPLC)

同義詞:

D-23129, N-(2-氨基-4-(4-氟苄基氨基)苯基)氨基甲酸乙酯, 依佐加滨

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C16H18FN3O2
CAS號碼:
分子量::
303.33
Beilstein:
8072099
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

藥物控制

USDEA Schedule V

顏色

white to light brown

溶解度

DMSO: >15 mg/mL

儲存溫度

room temp

SMILES 字串

FC1=CC=C(CNC2=CC(N)=C(NC(OCC)=O)C=C2)C=C1

InChI

1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)

InChI 密鑰

PCOBBVZJEWWZFR-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

生化/生理作用

瑞替加滨(依佐加滨)是一种具有抗惊厥活性的 Kv7.2-7.5 (KCNQ2-5)神经元钾通道开放剂。

象形圖

Skull and crossbonesEnvironment

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Ezogabine (Potiga) toxicity.
The Medical letter on drugs and therapeutics, 55(1430), 96-96 (2013-11-28)
Emma D Deeks
CNS drugs, 25(10), 887-900 (2011-09-23)
Retigabine (ezogabine in the US) opens neuronal voltage-gated potassium channels, resulting in resting membrane potential stabilization, neuronal subthreshold excitability control and anticonvulsant effects. The clinical efficacy of adjunctive oral retigabine in adults with inadequately controlled, partial-onset seizures was demonstrated in
Lyubov I Brueggemann et al.
Molecular pharmacology, 86(3), 330-341 (2014-06-20)
Recent research suggests that smooth muscle cells express Kv7.4 and Kv7.5 voltage-activated potassium channels, which contribute to maintenance of their resting membrane voltage. New pharmacologic activators of Kv7 channels, ML213 (N-mesitybicyclo[2.2.1]heptane-2-carboxamide) and ICA-069673 N-(6-chloropyridin-3-yl)-3,4-difluorobenzamide), have been reported to discriminate among
Michele Y Splinter
Clinical therapeutics, 34(9), 1845-1856 (2012-08-25)
Ezogabine, also known as retigabine, is a recently approved anticonvulsant medication with a novel mechanism of action. It activates low-threshold voltage-gated potassium channels, leading to hyperpolarization of the membrane potential, stabilization of the resting membrane potential, and suppression of repetitive
G Blackburn-Munro et al.
CNS drug reviews, 11(1), 1-20 (2005-05-04)
Retigabine [D23129; N-(2-amino-4-(4-fluorobenzylamino)-phenyl)carbamic acid ethyl ester] is an antiepileptic drug with a recently described novel mechanism of action that involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels. These channels (primarily K(V)7.2/7.3) enable generation of the M-current, a subthreshold

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務